The release of abstracts related to the upcoming Society for Immunotherapy in Cancer (SITC) meeting in Washington whetted investor appetite in many precincts of oncology, and an area of particular focus relates to a pair of sizzling therapeutic modalities: CRISPR/Cas9 and chimeric antigen receptor (CAR) T-cell therapies.